BioNTech and Pfizer’s Covid-19 vaccine has become the first approved vaccine made from messenger RNA.
The Medicines and Healthcare products Regulatory Agency (MHRA) has given BioNTech and Pfizer’s vaccine temporary authorization. This isn’t a full licensing — which takes longer to process and often requires more data — but allows an unlicensed vaccine to be used during the Covid-19 pandemic.
The authorization was made based on the results of a phase III clinical trial released in mid-November. According to the results, two doses of the vaccine around three weeks apart reduced Covid-19 cases by 95% compared to placebo. The partners now expect to roll out the first doses in the UK in the coming days.
“It is only 12 months since the first recorded case of Covid-19 and in that time, researchers around the world have worked tirelessly,” stated Arne Akbar, President of the British Society for Immunology, who was not involved in the vaccine’s development. “To achieve this within this timescale is remarkable.”
Two Covid-19 vaccines got the green light in Russia earlier this year. However, BioNTech and Pfizer’s vaccine is the first to get approval after undergoing phase III testing, and is also the first-ever approved medicine made of messenger RNA (mRNA).
The post UK First to Greenlight BioNTech and Pfizer mRNA Vaccine for Covid-19 appeared first on Labiotech.eu.
Published on Wed, 02 Dec 2020 17:10:36 +0000 and brought to you by power apps array ends with text